WB, IP
H
Endogenous
142
Rabbit
#Q96JA1
26018
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:100 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human
Species predicted to react based on 100% sequence homology
The antigen sequence used to produce this antibody shares
100% sequence homology with the species listed here, but
reactivity has not been tested or confirmed to work by CST.
Use of this product with these species is not covered under
our
Product Performance Guarantee.
Monkey
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human LRIG1 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Background
Leucine-rich immunoglobulin repeats 1 (LRIG1) is a type I transmembrane protein containing 15 leucine rich repeats and three immunoglobulin domains in the extracellular domain. Researchers characterize LRIG1 as a negative regulator of receptor tyrosine kinase signaling. In studies with ErbB family members and Met kinase, LRIG regulates signaling by increasing ubiquitination and lysosomal degradation of the receptors (1,2). Additional work indicates that LRIG1 plays a role in neurotropic signaling by negatively regulating Ret signaling (3,4). Expression profile studies demonstrate that LRIG1 is a marker in the quiescent population of stem cells in the intestine (5). Interestingly, the genetic ablation of one allele of LRIG1 in mice with an APC+/- background results in development of highly dysplastic adenomas, indicating a role for LRIG1 in tumor suppression (1). Indeed, down-regulation of LRIG1 is tentatively involved in tumor aggressiveness in several tumor types, including glioma (6), head and neck cancer (7), and cervical adenocarcinoma (8).
- Powell, A.E. et al. (2012) Cell 149, 146-58.
- Segatto, O. et al. (2011) J Cell Sci 124, 1785-93.
- Shattuck, D.L. et al. (2007) Mol Cell Biol 27, 1934-46.
- Ledda, F. et al. (2008) J Neurosci 28, 39-49.
- Muñoz, J. et al. (2012) EMBO J 31, 3079-91.
- Mao, F. et al. (2013) Int J Oncol 42, 1081-7.
- Sheu, J.J. et al. (2013) Oncogene 33, 1375-84.
- Muller, S. et al. (2013) Int J Oncol 42, 247-52.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
